Clinical Trial Detail

NCT ID NCT02376699
Title Safety Study of SEA-CD40 in Cancer Patients
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Seattle Genetics, Inc.
Indications

Hodgkin's lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Advanced Solid Tumor

lymphoma

Therapies

Pembrolizumab + SEA-CD40

SEA-CD40

Age Groups: senior adult

No variant requirements are available.